Clinical Trial Update: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III clinical trial evaluating ESG401 for unresectable recurrent or metastatic triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ESG401

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Triple-Negative Breast Cancer (TNBC) | Phase 3 | Status: RECRUITING